USPTO Examiner MOORE SUSANNA - Art Unit 1624

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
18673619O-GLYCOPROTEIN-2-ACETAMIDO-2-DEOXY-3-D-GLUCOPYRANOSIDASE INHIBITORSMay 2024December 2024Allow610YesNo
18634259NEUROACTIVE STEROIDS AND COMPOSITIONS THEREOFApril 2024March 2025Abandon1120NoNo
18583002LEUCINE-RICH REPEAT KINASE 2 (LRRK2) INHIBITORSFebruary 2024April 2025Abandon1410NoNo
18387420INHIBITORS OF MENIN-MLL INTERACTIONNovember 2023December 2024Allow1310YesNo
18386224BICYCLIC AMINES AS CDK2 INHIBITORSNovember 2023July 2025Allow2011NoNo
18496692SUBSTITUTED NICOTINIMIDE INHIBITORS OF BTK FOR TREATING CANCEROctober 2023July 2024Allow900NoNo
18487159CYCLIC AMIDE-CONTAINING PYRIDYL XANTHINES AS A2B ANTAGONISTSOctober 2023December 2024Allow1410YesNo
18467162LEUCINE-RICH REPEAT KINASE 2 (LRRK2) INHIBITORSSeptember 2023November 2023Allow200NoNo
18243068PYRROLO[2,3-C][1,6]NAPHTHYRIDINE-8-CARBOXYLIC ACID COMPOUNDS AS CK2 INHIBITORSSeptember 2023November 2023Allow201YesNo
182413505-SUBSTITUTED PYRIDO[3'',4'':4',5']PYRROLO[3',2':4,5]IMIDAZO[1,2-a]PYRAZINE COMPOUNDS AS CK2 INHIBITORSSeptember 2023November 2023Allow300YesNo
18365286PROTEIN KINASE B INHIBITORSAugust 2023November 2024Allow1511NoNo
18363600PHARMACEUTICAL FORMULATIONS FOR THE TREATMENT OF GASTROINTESTINAL DISORDERSAugust 2023May 2024Allow1011NoNo
18351752METHOD FOR PRODUCING CYCLIC IMIDE COMPOUND, COMPOSITION, AND COMPOUNDJuly 2023May 2025Allow2211YesNo
18347345SUBSTITUTED PIPERIDINE COMPOUND AND USE THEREOFJuly 2023December 2024Allow1810NoNo
18214327LSD DERIVATIVES, SYNTHESIS & METHOD FOR TREATMENT OF DISEASES AND DISORDERSJune 2023November 2024Allow1731YesNo
18196002MACROCYCLIC COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERSMay 2023December 2024Allow1911YesNo
18143720NITROGEN-CONTAINING SPIRO CYCLIC COMPOUNDS AND PHARMACEUTICAL USE THEREOFMay 2023June 2025Allow2511NoNo
18124827POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVEMarch 2023March 2024Allow1200YesNo
18185227PYRAZOLE MAGL INHIBITORSMarch 2023December 2024Allow2110NoNo
18176389PYRAZOLOPYRIMIDINE COMPOUNDS AS JAK INHIBITORSFebruary 2023November 2024Abandon2000YesNo
18112699PROCESS FOR THE PREPARATION OF SODIUM (2R,5S,13AR)-7,9-DIOXO-10-((2,4,6-TRIFLUOROBENZYL)CARBAMOYL)-2,3,4,5,7,9,13,13A-OCTAHYDRO-2,5-METHANOPYRIDO[1',2':4,5]PYRAZINO[2,1-B] [1,3] OXAZEPIN-8-OLATE AND ITS POLYMORPHIC FORMFebruary 2023May 2024Allow1401YesNo
18041731THERAPEUTIC PHENETHYLAMINE COMPOSITIONS AND METHODS OF USEFebruary 2023August 2024Allow1841YesNo
18166008BETULASTATIN COMPOUNDSFebruary 2023November 2024Allow2121YesNo
18101009GLYCYRRHETINIC ACID DERIVATIVES FOR TREATING HYPERKALEMIAJanuary 2023June 2024Allow1601NoNo
18157783METHODS FOR THE TREATMENT OF GASTRO-INTESTINAL DISORDERSJanuary 2023September 2023Allow810YesNo
18096392FUSED HETEROAROMATIC PYRROLIDINONESJanuary 2023January 2025Abandon2411NoNo
18086397Derivative of berberine, and the preparation method and application thereofDecember 2022November 2024Allow2321YesNo
18069646PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USESDecember 2022March 2024Allow1500NoNo
18083602Cyclopentathiophene Carboxamide Derivatives as Platelet Activating Factor Receptor AntagonistsDecember 2022March 2024Allow1521YesNo
18084208MORPHOLINYLPYRIDONE COMPOUNDSDecember 2022July 2024Abandon1920NoNo
18074889GLUCAGON RECEPTOR ANTAGONIST AND USE THEREOFDecember 2022June 2025Allow3000YesNo
17924792CRYSTALLINE SALT OF ERIBULINNovember 2022June 2025Allow3100YesNo
17997983FREE BASE CRYSTALSNovember 2022June 2025Allow3100YesNo
18050650BRIDGED TRICYCLIC CARBAMOYLPYRIDONE COMPOUNDS AND THEIR PHARMACEUTICAL USEOctober 2022August 2024Allow2221NoNo
18049344SPIROTRICYCLE RIPK1 INHIBITORS AND METHODS OF USES THEREOFOctober 2022July 2024Allow2121YesNo
17967483AZABENZIMIDAZOLES AND THEIR USE AS AMPA RECEPTOR MODULATORSOctober 2022June 2024Allow2010NoNo
17967508AZABENZIMIDAZOLES AND THEIR USE AS AMPA RECEPTOR MODULATORSOctober 2022June 2024Allow2010NoNo
17952460HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORSSeptember 2022May 2025Abandon3111NoNo
17933850METHOD FOR PREPARING 16ALPHA-HYDROXYPREDNISOLONESeptember 2022January 2023Allow400YesNo
17932876FUSED BICYCLIC COMPOUNDS FOR THE TREATMENT OF DISEASESeptember 2022July 2023Allow1011NoNo
17901007DOPAMINE-B-HYDROXYLASE INHIBITORSSeptember 2022December 2023Abandon1510NoNo
17823254NAPHTHYRIDINE COMPOUNDS AS INHIBITORS OF KRASAugust 2022June 2025Allow3431NoYes
17891869HEPATITIS C VIRUS NS3/4A PROTEASE INHIBITORSAugust 2022July 2024Abandon2321NoNo
17887325MATERIAL FOR THE TREATMENT OF GASTRO-INTESTINAL DISORDERSAugust 2022December 2022Allow411YesNo
17818873STEROIDS AND METHODS OF MANUFACTUREAugust 2022March 2025Allow3131YesNo
17878495ANTIBACTERIAL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF TREATING BACTERIAL INFECTIONSAugust 2022May 2023Allow901YesNo
17874324Novel compounds and their use in therapyJuly 2022January 2024Abandon1811NoNo
17873248NEAR-INFRARED FLUORESCENT INDICATORS FOR LYSOSOME AND APPLICATION THEREOFJuly 2022December 2022Allow500YesNo
17870885SEROTONIN 5-HT2B INHIBITORY COMPOUNDSJuly 2022December 2024Allow2941YesNo
17870156Bicyclic Pyridin-2-one and pyrimidin-4-one Derivatives Useful As a Factor XIa InhibitorsJuly 2022February 2025Abandon3121NoNo
17814224HETEROCYCLIC COMPOUNDS USEFUL AS PDK1 INHIBITORSJuly 2022June 2024Abandon2311NoNo
178701515-oxo-1,2,3,5,8,8a-hexahydroindolizine-3-carboxamide Derivatives Useful As a Factor XIa InhibitorsJuly 2022December 2024Allow2921YesNo
17813805TYK2 INHIBITORS AND USES THEREOFJuly 2022April 2024Abandon2011NoNo
17864106MAP4K1 INHIBITORSJuly 2022June 2024Allow2321YesNo
17810915TRICYCLIC COMPOUNDS AS INHIBITORS OF KRASJuly 2022May 2025Allow3531NoYes
17855672THYROID HORMONE RECEPTOR BETA AGONIST COMPOUNDSJune 2022October 2023Abandon1601NoNo
17790042PROCESS FOR THE SYNTHESIS OF BUPRENORPHINEJune 2022November 2023Allow1610NoNo
17853647AhR MODULATORSJune 2022November 2024Allow2931NoNo
17850668SUBSTITUTED [1,2,4]TRIAZOLO[1,5-A]PYRIMIDIN-7-YL COMPOUNDS AS PDE2 INHIBITORSJune 2022July 2024Abandon2510NoNo
17831760(17-)-3-Oxoandrost-4-EN-17-YL Dodecanoate Compositions and Methods of Preparation and UseJune 2022May 2025Allow3541YesYes
17781095METHOD FOR SYNTHESIZING URSODEOXYCHOLIC ACID USING BA AS RAW MATERIALMay 2022June 2025Allow3701YesNo
17804012SUBSTITUTED NICOTINIMIDE INHIBITORS OF BTK FOR TREATING CANCERMay 2022July 2023Allow1420YesNo
17748470TETRACYCLIC COMPOUNDS AND METHODS FOR THE TREATMENT OF ZIKA VIRUS INFECTIONMay 2022December 2023Abandon1910NoNo
17746446BRAF INHIBITORS AND USE THEREOF FOR TREATMENT OF CUTANEOUS REACTIONSMay 2022October 2023Abandon1701NoNo
17663551CYCLIC AMIDE-CONTAINING PYRIDYL XANTHINES AS A2B ANTAGONISTSMay 2022June 2023Allow1311YesNo
17660355MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USEApril 2022October 2023Abandon1801NoNo
17655293METHOD FOR PRODUCING CYCLIC IMIDE COMPOUND, COMPOSITION, AND COMPOUNDMarch 2022August 2024Allow2921YesNo
17694757MACROCYCLIC FLU ENDONUCLEASE INHIBITORSMarch 2022October 2023Abandon1910NoNo
17689510HETEROARYL SUBSTITUTED PYRROLO[2,3-b]PYRIDINES AND PYRROLO[2,3-b]PYRIMIDINES AS JANUS KINASE INHIBITORSMarch 2022March 2023Allow1300YesNo
17687826BENZAZOLE COMPOUNDS AND METHODS FOR MAKING AND USING THE COMPOUNDSMarch 2022March 2024Allow2421YesNo
17640506SIDEROPHORE CEPHALOSPORIN CONJUGATES AND USES THEREOFMarch 2022March 2025Allow3600YesNo
17652076LUMATEPERONE BIS-TOSYLATE SALTS AND CRYSTALS AND METHODS FOR MANUFACTURE THEREOFFebruary 2022September 2024Allow3121YesYes
176749431-CYANO-PYRROLIDINE DERIVATIVES AS DUB INHIBITORSFebruary 2022January 2024Allow2321NoNo
17417613PYRAZOLO[1,5-A]PYRIMIDINE MACROCYCLIC COMPOUNDFebruary 2022June 2023Allow2300YesNo
17635928MACROCYCLIC SULFONYLAMIDE DERIVATIVES USEFUL AS NLRP3 INHIBITORSFebruary 2022January 2025Abandon3521NoNo
17636014MACROCYCLIC SULFONYLUREA DERIVATIVES USEFUL AS NLRP3 INHIBITORSFebruary 2022January 2025Abandon3521NoNo
17650155P2X7 MODULATORSFebruary 2022February 2025Allow3641NoYes
17648045PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODSJanuary 2022January 2024Abandon2411NoNo
17574132SMALL MOLECULE MYRISTATE INHIBITORS OF BCR-ABL AND METHODS OF USEJanuary 2022November 2023Allow2231YesNo
17625494METASTABLE CRYSTAL MODIFICATION AND METHOD FOR PRODUCING THE SAME (I)January 2022July 2022Allow710YesNo
17623252REFINING METHOD OF MIDBODY OF LATAMOXEF SODIUMDecember 2021April 2025Allow3910YesNo
17623041IMPROVED PROCESS FOR THE PREPARATON OF PURE (1'R,6R,6aR,7R,13S,14S,16R)-5-(ACETYLOXY)-3',4',6,6a,7,13,14,16-OCTAHYDRO-6',8,14-TRIHYDROXY-7',9-DIMETHOXY-4,10,23-TRIMETHYLSPIRO[6,16-(EPITHIOPROPANOXYMETH ANO)-7,13-IMINO-12H-1,3-DIOXOLO[7,8]ISOQUINO[3,2-b][3]BENZAZOCINE-20,1'(2'H)-ISOQUINOLIN]-19-ONE POLYMORPH THERE OFDecember 2021December 2024Abandon3621NoNo
17557174NITROGEN-CONTAINING SPIRO CYCLIC COMPOUNDS AND PHARMACEUTICAL USES THEREOFDecember 2021June 2023Abandon1801NoNo
17621023PROCESS FOR THE PREPARATION OF A METASTABLE CRYSTAL MODIFICATION OF N-(AMINOIMINOMETHYL)-2-AMINOACETIC ACID (III)December 2021December 2024Allow3611YesNo
17620410ANALOGUES OF 3-(5-METHYL-1,3-THIAZOL-2-YL)-N-{(1R)-1-[2-(TRIFLUORO-METHYL)PYRIMIDIN-5-YL]ETHYL}BENZAMIDEDecember 2021April 2025Abandon4001NoNo
17620239EGFR INHIBITOR FOR THE TREATMENT OF CANCERDecember 2021April 2025Allow4020YesNo
17644654PROTEIN KINASE B INHIBITORSDecember 2021July 2023Allow1911NoNo
17596674HETEROCYCLIC DERIVATIVES AND USE THEREOFDecember 2021April 2025Abandon4001NoNo
17617851CGRP ANTAGONIST COMPOUNDSDecember 2021October 2024Allow3400YesNo
17546133SOLID FORMS OF 2-(5-(4-(2-MORPHOLINOETHOXY)PHENYL)PYRIDIN-2-YL)-N-BENZYLACETAMIDEDecember 2021September 2024Allow3421NoNo
17536925Salts of the Janus Kinase Inhibitor (R)-3-(4-(7h-Pyrrolo[2,3-D]Pyrimidin-4-YL)-1h-Pyrazol-1-Yl)-3- CyclopentylpropanenitrileNovember 2021May 2024Abandon3020NoNo
17595651CRYSTAL FORM OF PYRIMIDINE SULFONAMIDE COMPOUND AND PREPARATION METHOD THEREFORNovember 2021September 2024Allow3400YesNo
17455507FGFR INHIBITORS AND METHODS OF MAKING AND USING THE SAMENovember 2021March 2024Allow2821YesNo
17519590SYNTHESIS OF ERIBULIN MESYLATENovember 2021April 2023Allow1800NoNo
17604194DERIVATIVES OF ADAMANTYL OXADIAZOLES AND PHARMACEUTICALLY ACCEPTABLE SOLVATES, HYDRATES AND SALTS THEREOF, PHARMACEUTICAL COMPOSITION COMPRISING SAME, SYNTHESIS METHOD, SUITABLE FOR USE AS EFFECTIVE AND SELECTIVE INHIBITORS OF THE REDUCTASE ACTIVITY OF THE ENZYME 11-BETA DEHYDROGENASE TYPE 1 (11B-HSD1)October 2021March 2025Allow4120NoNo
17499230Pyrimidine or Pyridine Compounds, Preparation Method Therefor and Pharmaceutical Uses ThereofOctober 2021May 2022Allow720YesNo
17601390METHODS OF TREATING NEUROPATHIC PAINOctober 2021June 2025Abandon4420NoNo
17449779HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORSOctober 2021October 2023Abandon2511NoNo
17488317Preparation and Application of A 5-bromoquinazoline DerivativeSeptember 2021August 2023Allow2320NoNo
17441788TYK2 PSEUDOKINASE LIGANDSSeptember 2021May 2023Allow2000YesNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner MOORE, SUSANNA.

Strategic Value of Filing an Appeal

Total Appeal Filings
77
Allowed After Appeal Filing
18
(23.4%)
Not Allowed After Appeal Filing
59
(76.6%)
Filing Benefit Percentile
28.3%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 23.4% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is below the USPTO average, suggesting that filing an appeal has limited effectiveness in prompting favorable reconsideration.

Strategic Recommendations

Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Examiner MOORE, SUSANNA - Prosecution Strategy Guide

Executive Summary

Examiner MOORE, SUSANNA works in Art Unit 1624 and has examined 1,574 patent applications in our dataset. With an allowance rate of 66.8%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 31 months.

Allowance Patterns

Examiner MOORE, SUSANNA's allowance rate of 66.8% places them in the 20% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.

Office Action Patterns

On average, applications examined by MOORE, SUSANNA receive 1.62 office actions before reaching final disposition. This places the examiner in the 44% percentile for office actions issued. This examiner issues fewer office actions than average, which may indicate efficient prosecution or a more lenient examination style.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by MOORE, SUSANNA is 31 months. This places the examiner in the 34% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.

Interview Effectiveness

Conducting an examiner interview provides a +41.9% benefit to allowance rate for applications examined by MOORE, SUSANNA. This interview benefit is in the 90% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 27.9% of applications are subsequently allowed. This success rate is in the 40% percentile among all examiners. Strategic Insight: RCEs show below-average effectiveness with this examiner. Carefully evaluate whether an RCE or continuation is the better strategy.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 61.0% of cases where such amendments are filed. This entry rate is in the 83% percentile among all examiners. Strategic Recommendation: This examiner is highly receptive to after-final amendments compared to other examiners. Per MPEP § 714.12, after-final amendments may be entered "under justifiable circumstances." Consider filing after-final amendments with a clear showing of allowability rather than immediately filing an RCE, as this examiner frequently enters such amendments.

Pre-Appeal Conference Effectiveness

When applicants request a pre-appeal conference (PAC) with this examiner, 111.1% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 78% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences are highly effective with this examiner compared to others. Before filing a full appeal brief, strongly consider requesting a PAC. The PAC provides an opportunity for the examiner and supervisory personnel to reconsider the rejection before the case proceeds to the PTAB.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 100.0% of appeals filed. This is in the 85% percentile among all examiners. Of these withdrawals, 89.4% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.

Petition Practice

When applicants file petitions regarding this examiner's actions, 56.1% are granted (fully or in part). This grant rate is in the 71% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 10.9% of allowed cases (in the 96% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.

Quayle Actions: This examiner issues Ex Parte Quayle actions in 3.8% of allowed cases (in the 75% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Prepare for rigorous examination: With a below-average allowance rate, ensure your application has strong written description and enablement support. Consider filing a continuation if you need to add new matter.
  • Prioritize examiner interviews: Interviews are highly effective with this examiner. Request an interview after the first office action to clarify issues and potentially expedite allowance.
  • Consider after-final amendments: This examiner frequently enters after-final amendments. If you can clearly overcome rejections with claim amendments, file an after-final amendment before resorting to an RCE.
  • Request pre-appeal conferences: PACs are highly effective with this examiner. Before filing a full appeal brief, request a PAC to potentially resolve issues without full PTAB review.
  • Appeal filing as negotiation tool: This examiner frequently reconsiders rejections during the appeal process. Filing a Notice of Appeal may prompt favorable reconsideration during the mandatory appeal conference.
  • Examiner cooperation: This examiner frequently makes examiner's amendments to place applications in condition for allowance. If you are close to allowance, the examiner may help finalize the claims.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.